Navigation Links
Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
Date:2/25/2008

MELBOURNE, Australia, Feb. 26 /PRNewswire/ -- Bionomics Limited (ASX: BNO) today announced the initiation of treatment for the first patient in the Phase I trial of its anti-cancer drug, BNC105.

The BNC105 Phase I clinical trial involves treatment of patients with advanced cancer. Patients will be treated with BNC105 on days 1 and 8 of a 21 day cycle, over two cycles. The trial will be conducted at clinical sites within the Cancer Trials Australia network at the Royal Melbourne Hospital, the Peter MaCallum Cancer Centre and the Western Hospital in Melbourne.

Dr. Deborah Rathjen, CEO and Managing Director of Bionomics hailed the commencement of the Phase I trial as a significant milestone for the Company.

"We are excited to commence our trial of BNC105 and to announce our first patient has begun treatment," Dr Rathjen commented. "We will provide regular updates as we move through the trial, and I look forward to updating shareholders on our progress."

The primary objective for this trial is the evaluation of the safety and tolerability of BNC105. The results obtained from this trial will enable the identification of an appropriate dose of BNC105 for subsequent trials. Further objectives include, the evaluation of BNC105 pharmacokinetics and its activity against tumour vasculature and tumour growth.

BNC105 is a new type of anti-cancer drug called a Vascular Disruption Agent (VDA) which blocks the blood supply to a solid tumour, effectively "starving" the tumour of nutrients. Pre-clinical data indicates that BNC105 has a dual mechanism of action with the ability to not only block the supply of nutrients to the tumour but also to directly destroy cancer cells. In addition, BNC105 is retained in the tumour at high levels for an extended period of time, enhancing its' anti-cancer effect.

Although VDAs have strong potential for use in combination with traditional cancer treatment options, including chemotherapy, preclinical
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Decision Resources Group finds ... Memphis health system and hospital ... integration, with rivals Methodist Le Bonheur Healthcare and Baptist ... to coordinate patient care. In addition, a national contract ... most health plan enrollment in the Memphis ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Heart Valve Repair and Replacement ... About Heart Valve Repair and Replacement ... which control the flow of blood during the ... diseases such as valvular stenosis, valvular insufficiency or ...
(Date:8/27/2014)... Reportlinker.com announces that a new market research ... Food Eastern Europe 2014 http://www.reportlinker.com/p02312454/Baby-Food-Eastern-Europe-2014.html ... is a new report by ERC that analyzes the ... Europe , key segments, features & developments, future ... trends which are currently affecting the industry. Furthermore, it ...
Breaking Medicine Technology:Memphis-area Health Systems Turn Attention to Clinical Integration 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8
... demonstrated better symptom control versus Concerta from 30 minutes to six ... effect as early as 30 minutes post-dose, - Additional analysis suggests Focalin XR ... ... Disorder (ADHD) can,significantly impact a child,s ability to focus and learn in an ...
... Presence Includes ANA598 and ANA773 Acting via ... ... PDT, SAN DIEGO, July 7 Anadys Pharmaceuticals,Inc. (Nasdaq: ... Toll-Like Receptor-7 (TLR7) mechanism for the,treatment of chronic hepatitis C. Based ...
Cached Medicine Technology:Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 2Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 3Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 4Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 5Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 6Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 7Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 8Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5
(Date:8/27/2014)... -- In a new study done from the heights ... pressure steadily increases if you ascend to great heights. ... to treat high blood pressure was ineffective once climbers ... online Aug. 27 in the European Heart Journal ... at sea level who have sleep apnea, in which ...
(Date:8/27/2014)... Some 30 percent of all positive hospital blood culture ... they reflect the presence of skin germs instead of ... compromised samples into the trash, clinicians may be able ... by these tests to treat patients with antibiotics appropriate ... Gidi Stein and Dr. Danny Alon of TAU,s Sackler ...
(Date:8/27/2014)... (WASHINGTON, August, 27, 2014) An experimental drug designed to ... viable first treatment for anemia of inflammation, according to results ... published online today in Blood , the ... Anemia is a condition that occurs when red blood cells ... an individual has anemia, the body does not get enough ...
(Date:8/27/2014)... prevent the onset of a cancer defense mechanism ... Massey Cancer Center are leveraging it in a ... in cell death rather than survival. The novel ... often referred to as the "Trash Man" due ... during autophagy. Results from preclinical experiments suggest this ...
(Date:8/27/2014)... 27, 2014 Jaha was founded with a ... invested in creating the industry’s most affordable fitness tracker together ... no other apps possess. Jaha plans to announce ... in three simple steps: locate, challenge and motivate. ... 26, 2014 to garner support and to raise awareness on ...
Breaking Medicine News(10 mins):Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:'Junk' blood tests may offer life-saving information 2Health News:Drug represents first potential treatment for common anemia 2Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2Health News:Jaha, Inc. The Most Affordable Fitness Band in the Market Released on Kickstarter 2
... decades-long study of monkeys on a restricted diet is ... life. Writing today (July 10) in the journal ... University of Wisconsin-Madison, the Wisconsin National Primate Research Center ... that a nutritious but reduced-calorie diet blunts aging and ...
... ... have been avoidable, and New York personal injury attorney David Perecman is on the alert. ... New York, NY (PRWEB) June 29, 2009 ... nine people and injured at least 79, according to the latest news update from The ...
... Specialty Hospitals of America (SHA) and the Specialty Hospital of ... the Skilled Nursing Facility (SNF) at UMC in South East DC. ... live, should have access to high-quality nursing home care," said Eric ... President of UMC. "The new Skilled Nursing Center is one ...
... , WASHINGTON, July 9 The Walmart Foundation ... of the National Organization on Disability,s (N.O.D.) Emergency Preparedness ... and the disability community as the only cross-disability organization ... experienced in emergency management and disability issues. , ...
... Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), ... tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring ... M.D., Chairman and Chief Executive Officer, will present at the ... 5:30 pm ET. The presentation will occur live and ...
... nation,s leading health experts insist that we drink plenty of ... this advice may actually increase a person,s risk for the ... Myth" in the August issue of Natural Solutions: Vibrant ... 1,200 studies showing that neither milk nor a high-calcium diet ...
Cached Medicine News:Health News:Reduced diet thwarts aging, disease in monkeys 2Health News:Reduced diet thwarts aging, disease in monkeys 3Health News:Washington D.C. Metro Crash Jolts Personal Injury Attorneys from Coast to Coast 2Health News:Washington D.C. Metro Crash Jolts Personal Injury Attorneys from Coast to Coast 3Health News:Specialty Hospitals of Washington Adds Additional Skilled Nursing Facility Beds at United Medical Center in South East DC 2Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 2Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 3Health News:Echo Therapeutics To Present at Prestigious 'Innovations in Diabetes' Conference 2Health News:Echo Therapeutics To Present at Prestigious 'Innovations in Diabetes' Conference 3Health News:Calcium Isn't the Secret to Healthy Bones, Says Natural Solutions Magazine 2
... new dedicated high performance bio imaging system ... process of imaging chemiluminescent samples. It provides ... to use, thanks to new, unique image ... on the standard Genegnome, the Genegnome HR ...
... dedicated high performance bio imaging ... completely automates the process of ... superbly accurate results and is ... image analysis algorithms and powerful ...
... of Platelet aggregometers allows to choose ... needs. Single, dual and four sample ... outputs or digital computer outputs. In ... which measure platelet aggregation in platelet-rich-plasma ...
... Platelet aggregometers allows to choose the ... Single, dual and four sample units ... or digital computer outputs. In addition ... measure platelet aggregation in platelet-rich-plasma (PRP), ...
Medicine Products: